Virtus LifeSci Biotech Clinical Trials ETF
12 hedge funds and large institutions have $9.17M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
1.85% more ownership
Funds ownership: 27.44% → 29.29% (+1.9%)
Holders
12
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$685K | |
| 2 | +$600K | |
| 3 | +$484K | |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$42.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$20K |
Top Sellers
| 1 | -$686K | |
| 2 | -$243K | |
| 3 | -$15K | |
| 4 |
LPL Financial
San Diego,
California
|
-$14.1K |